NASDAQ:SLN

Silence Therapeutics (SLN) Stock Forecast, Price & News

$5.40

-0.31 (-5.43%)

(As of 06/2/2023 ET)

Compare

Today's Range: $5.20
▼
$5.81
50-Day Range: $4.61
▼
$9.19
52-Week Range: $4.55
▼
$17.99

Volume: 34,884 shs
Average Volume: 60,763 shs
Market Capitalization: $161.62 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $44.75

Silence Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 728.7% Upside
$44.75 Price Target
Short Interest: Healthy
0.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.83) to ($1.99) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

449th out of 983 stocks

Pharmaceutical Preparations Industry

215th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Silence Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $44.75, Silence Therapeutics has a forecasted upside of 728.7% from its current price of $5.40.
Amount of Analyst Coverage
Silence Therapeutics has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.08% of the float of Silence Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Silence Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Silence Therapeutics has recently decreased by 36.72%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Silence Therapeutics does not currently pay a dividend.
Dividend Growth
Silence Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SLN.

3.4

News and Social Media Coverage

News Sentiment
Silence Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
Search Interest
3 people have searched for SLN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
2 people have added Silence Therapeutics to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Silence Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.95% of the stock of Silence Therapeutics is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Silence Therapeutics are expected to decrease in the coming year, from ($1.83) to ($1.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Silence Therapeutics is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Silence Therapeutics is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Silence Therapeutics has a P/B Ratio of 8.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Silence Therapeutics (NASDAQ:SLN) Stock

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLN Stock News Headlines

May 24, 2023 | americanbankingnews.com

William Blair Comments on Silence Therapeutics plc's Q2 2023 Earnings (NASDAQ:SLN)

May 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Services Companies: Silence Therapeutics (SLN), Paypal Holdings (PYPL) and Liberty Global C (LBTYK)

June 2, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.

May 8, 2023 | msn.com

Silence Therapeutics overweight at Morgan Stanley on RNAi platform

May 8, 2023 | markets.businessinsider.com

Analysts Conflicted on These Services Names: Silence Therapeutics (SLN) and Planet Fitness (PLNT)

May 8, 2023 | americanbankingnews.com

Morgan Stanley Begins Coverage on Silence Therapeutics (NASDAQ:SLN)

March 31, 2023 | americanbankingnews.com

Silence Therapeutics plc (NASDAQ:SLN) Forecasted to Post FY2025 Earnings of ($2.04) Per Share

March 29, 2023 | msn.com

American Depositary Receipts of European Equities Rise As Banking Sector Worries Ease

June 2, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

March 29, 2023 | finance.yahoo.com

Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days

March 21, 2023 | americanbankingnews.com

Silence Therapeutics (NASDAQ:SLN) Stock Rating Reaffirmed by HC Wainwright

March 20, 2023 | insidermonkey.com

Silence Therapeutics plc (NASDAQ:SLN) Q4 2022 Earnings Call Transcript

March 16, 2023 | nypost.com

Tweet from Aaron Rodgers’ account prompts confusion after breaking silence

March 15, 2023 | finanznachrichten.de

Silence Therapeutics plc: Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results

March 15, 2023 | businesswire.com

Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results

March 13, 2023 | seekingalpha.com

SLN Silence Therapeutics plc

March 6, 2023 | theguardian.com

Covert cameras and alleged hacking: how bust payments company Wirecard ‘hired spies and lawyers to silence critics’

March 6, 2023 | finance.yahoo.com

Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?

March 2, 2023 | businesswire.com

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023

January 19, 2023 | finance.yahoo.com

Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics

January 4, 2023 | finance.yahoo.com

Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock?

January 3, 2023 | finance.yahoo.com

Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 6, 2022 | msn.com

What’s Changed Since TIME Named the ‘Silence Breakers’ Person of the Year

November 7, 2022 | msn.com

‘The Opposite of Fear Is Love’: Christos Passalis on Grief and Healing in Thessaloniki Competition Title ‘Silence 6-9’

November 5, 2022 | finance.yahoo.com

Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

October 7, 2022 | finance.yahoo.com

Silence Therapeutics' Thalassemia Hopeful Shows Favorable Safety Profile In Early Stage Study

September 22, 2022 | latimes.com

Column: Amid the pageantry and corgis, what made the queen’s funeral extraordinary was silence

See More Headlines

SLN Price History

30 days | 90 days | 365 days | Advanced Chart

SLN Company Calendar

Last Earnings: 3/15/2023
Today: 6/02/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SLN
CUSIP: N/A
CIK: 1479615
Web: www.silence-therapeutics.com
Phone: 44-0-20-3457-6900
Fax: N/A
Employees: 105
Year Founded: 1999

Price Target and Rating

Average Stock Price Forecast: $44.75
High Stock Price Forecast: $80.00
Low Stock Price Forecast: $20.00
Forecasted Upside/Downside: +728.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,080,000.00
Net Margins: -185.71%
Pretax Margin: -218.65%
Return on Equity: -254.24%
Return on Assets: -41.68%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 4.71
Quick Ratio: 4.71

Sales & Book Value

Annual Sales: $21.65 million
Price / Sales: 7.47
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.67 per share
Price / Book: 8.06

Miscellaneous

Outstanding Shares: 29,930,000
Free Float: 29,045,000
Market Cap: $161.62 million
Optionable: Not Optionable
Beta: 0.74

Social Links

Key Executives

Mr. Craig A. Tooman M.B.A. (Age 56)
MBA, Pres, CEO & Exec. Director
Comp: $481.48k

Ms. Rhonda L. Hellums (Age 50)
Chief Financial Officer
Comp: $270.1k

Dr. Giles V. Campion M.D. (Age 68)
Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director
Comp: $617.91k

Ms. Gem Gokmen Hopkins
Head of IR & Corp. Communications

Dr. John Strafford Ph.D.
Sr. VP of Bus. Devel., Alliance Management & New Product Devel.

Mr. Jørgen Wittendorff
Sr. VP & Head of Manufacturing

Dr. Barbara A. Ruskin J.D. (Age 62)
Ph.D., Sr. VP and Chief Intellectual Property & Innovation Officer

Dr. Eric Floyd Ph.D. (Age 60)
Sr. VP of Regulatory Affairs & Quality Assurance

Dr. Marie Wikstrom Lindholm Ph.D.
Sr. VP & Head of Molecular Design

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SLN Stock - Frequently Asked Questions

Should I buy or sell Silence Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLN shares.
View SLN analyst ratings or view top-rated stocks.
What is Silence Therapeutics' stock price forecast for 2023?: 3 brokerages have issued twelve-month price objectives for Silence Therapeutics' shares. Their SLN share price forecasts range from $20.00 to $80.00. On average, they predict the company's share price to reach $44.75 in the next twelve months. This suggests a possible upside of 728.7% from the stock's current price.
View analysts price targets for SLN or view top-rated stocks among Wall Street analysts.
How have SLN shares performed in 2023?: Silence Therapeutics' stock was trading at $15.25 at the start of the year. Since then, SLN stock has decreased by 64.6% and is now trading at $5.40.
View the best growth stocks for 2023 here.
Are investors shorting Silence Therapeutics?: Silence Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 22,400 shares, a decline of 36.7% from the April 30th total of 35,400 shares. Based on an average trading volume of 74,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.1% of the shares of the stock are sold short.
View Silence Therapeutics' Short Interest.
When is Silence Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our SLN earnings forecast.
How were Silence Therapeutics' earnings last quarter?: Silence Therapeutics plc (NASDAQ:SLN) announced its earnings results on Wednesday, March, 15th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by $0.91. The firm had revenue of $5.59 million for the quarter, compared to analyst estimates of $36.30 million. Silence Therapeutics had a negative net margin of 185.71% and a negative trailing twelve-month return on equity of 254.24%.

What is Silence Therapeutics' stock symbol?: Silence Therapeutics trades on the NASDAQ under the ticker symbol "SLN."
Who are Silence Therapeutics' major shareholders?: Silence Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include AXA S.A. (1.73%) and Schonfeld Strategic Advisors LLC (0.14%).
How do I buy shares of Silence Therapeutics?: Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Silence Therapeutics' stock price today?: One share of SLN stock can currently be purchased for approximately $5.40.
How much money does Silence Therapeutics make?: Silence Therapeutics (NASDAQ:SLN) has a market capitalization of $161.62 million and generates $21.65 million in revenue each year. The company earns $-50,080,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.
How many employees does Silence Therapeutics have?: The company employs 105 workers across the globe.
How can I contact Silence Therapeutics?: Silence Therapeutics' mailing address is 72 HAMMERSMITH ROAD, LONDON X0, W14 8TH. The official website for the company is www.silence-therapeutics.com. The company can be reached via phone at 44-0-20-3457-6900.

This page (NASDAQ:SLN) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial